Evidence map›Paper›PMID 33574416›Full record

ArticleScientific reports2021

Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2.

Ewelina Weglarz-Tomczak, Jakub M Tomczak, Michał Talma, Małgorzata Burda-Grabowska, Mirosław Giurg, Stanley Brul

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04483973 phase2completednot on this map

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients

TypeinterventionalSponsorSound Pharmaceuticals, IncorporatedRan2021 to 2023Enrolled25ConditionsCovid19, Coronavirus, Coronavirus Infection, Corona Virus InfectionArmsEbselen, Placebo
NCT04484025 phase2enrolling by invitationnot on this map

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients

TypeinterventionalSponsorSound Pharmaceuticals, IncorporatedRan2021 to 2023Enrolled60ConditionsCovid19, Corona Virus Infection, Coronavirus, Coronavirus InfectionArmsEbselen, Placebo
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 126 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Exploring the Therapeutic Potential ofMolecules (Basel, Switzerland) · 2024
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Host factors of SARS-CoV-2 in infection, pathogenesis, and long-term effects.Frontiers in cellular and infection microbiology · 2024
    Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Ewelina Weglarz-TomczakMolecular Biology and Microbial Food Safety Group, Swammerdam Institute for Life Sciences, Faculty of Science, University of Amsterdam, Amsterdam, The Netherlands. ewelina.weglarz.tomczak@gmail.com.
Jakub M TomczakComputational Intelligence Group, Department of Computer Science, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Michał TalmaDepartment of Bioorganic Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wrocław, Poland.
Małgorzata Burda-GrabowskaDepartment of Bioorganic Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wrocław, Poland.
Mirosław GiurgDepartment of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wrocław, Poland.
Stanley BrulMolecular Biology and Microbial Food Safety Group, Swammerdam Institute for Life Sciences, Faculty of Science, University of Amsterdam, Amsterdam, The Netherlands. s.brul@uva.nl.
AGH University of Krakow · PLUniversity of Amsterdam · NLVrije Universiteit Amsterdam · NLWrocław University of Science and Technology · PL

Funding

Ministerstwo Nauki i Szkolnictwa Wyższego 1639/MOB/V/2017/0Politechnika Wrocławska 82013902
6 · The paper itself

Abstract

An efficient treatment against a COVID-19 disease, caused by the novel coronavirus SARS-CoV-2 (CoV2), remains a challenge. The papain-like protease (PL

Indexed as

Molecular Docking SimulationAntiviral AgentsAzolesBinding SitesCoronavirus Papain-Like ProteasesIsoindolesOrganoselenium CompoundsProtease InhibitorsProtein BindingAntiviral AgentsAzolesCoronavirus Papain-Like ProteasesebselenIsoindolesOrganoselenium Compoundspapain-like protease, SARS-CoV-2Protease Inhibitors

Identifiers

PMID33574416
PMCPMC7878891
OpenAlexW3127827812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.